We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NVNO:NASDAQenVVeno Medical Corporation Analysis

Data as of 2026-06-11 - not real-time

$10.27

Latest Price

8/10Risk

Risk Level: High

Executive Summary

NVNO is trading well below its short‑term and long‑term moving averages, with a bearish MACD crossover and an RSI hovering in the neutral zone. The price sits near a technical support area and faces resistance just above the current level, while volume has been on a downward trend and 30‑day volatility remains extremely high. Fundamentally, the company reports negative earnings, a negative forward P/E, and a very low price‑to‑book ratio, indicating a distressed valuation despite a modest cash position and limited debt.
The recent FDA IDE approval for a pivotal non‑surgical venous valve study provides a potential catalyst that could shift sentiment, but the lack of revenue and operating cash outflows keep the risk profile elevated.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price below short‑term moving averages
  • bearish MACD signal
  • pending clinical data from FDA‑approved study

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • potential revenue lift if pivotal trial succeeds
  • significant upside from low price‑to‑book valuation
  • continued cash buffer despite operating losses

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • breakthrough medical‑device positioning in venous disease
  • long‑term market opportunity if product gains regulatory clearance
  • structural undervaluation relative to book value

Key Metrics & Analysis

Financial Health

P/E Ratio-8.6
ROE-60.65%
ROA-37.51%
Debt/Equity2.54
P/B Ratio0.3
Op. Cash Flow$-14788000
Free Cash Flow$-8367375
Industry P/E24.7

Technical Analysis

TrendBearish
RSI45.0
Support$9.04
Resistance$11.33
MA 20$10.54
MA 50$10.83
MA 200$16.16
MACDBearish
VolumeDecreasing
Fear & Greed Index84.2

Valuation

GradeUndervalued
TypeValue

Risk Assessment

Beta2.04
Volatility62.49%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.